Varicella vaccination in England and Wales: Cost-utility analysis

Archives of Disease in Childhood

Volumn 88, Issue 10, 2003, Pages 862-869

  Brisson, M ^a,b   Edmunds, W J ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

AGE DETERMINATION; AGE DISTRIBUTION; ARTICLE; CHICKENPOX; CHILDHOOD MORTALITY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DISEASE MODEL; DRUG COST; HEALTH CARE COST; HEALTH SURVEY; HERPES ZOSTER; HOSPITALIZATION; MEDICAL ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; ENGLAND; HEALTH CARE COSTS; HERPES ZOSTER; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; VACCINATION; WALES;

EID: 0141525183     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.10.862     Document Type: Article

References (29)

1. Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: review of the literature. Pharmacoeconomics. 2003;21:13-38.
2. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
3. Beutels P, Clara R, Tormans G, et al. Costs and benefits of routine varicella vaccination in Geman children. J Infect Dis 1996;174(suppl 3):S335-41.
4. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000;18:407-15.
5. Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999;17:142-51.
6. Brisson M, Edmunds WJ. The cost-effectiveness of varicella zoster virus (VZV) vaccination in Canada. Vaccine 2002;20:1113-25.
7. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-12.
8. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002;360:678-82.
9. Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500-7.
10. Brisson M, Edmunds WJ, Gay NJ, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000;125:651-9.
11. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 2003;70:(suppl 1):S31-7.
12. Brisson M, Edmunds WJ. Epidemiology of varicella zoster virus in England and Wales. J Med Virol 2003;70(suppl 1):S9-14.
13. Izurieto HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495-9.
14. Bernstein HH, Rothstein EP, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993;92:833-7.
15. Wise RP, Salive Me, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284:1271-9.
16. Office for National Statistics. Twentieth century mortality. CD-ROM. London: HMSO, 2000.
17. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90.
18. NHS Executive. Health Service Cost Index. Appendix 1. NHS finance manual. London: Department of Health, 2001.
19. Netten A, Curtis L. Unit costs of health and social care. Canterbury: PSSRU, 2001.
20. Wreghitt TG, Whipp J, Redpath C, et al. An analysis of infection control of varicella-zoster virus infection in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92. Epidemiol Infect 1996;117:165-71.
21. Department of Health Statistics Division. Prescription cost analysis 1998: England. London: HMSO, 1999:165.
22. Fornaro P, Gandini F, Marin M, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis J 1999;18:414-19.
23. Saddier P, Floret D, Guess HA, et al. Cost of varicella in France: a study in day care centers. J Infect Dis 1998;178:S58-63.
24. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: Part I. Cost of uncomplicated cases. Pediatrics 1999;104:1-6.
25. Office for National Statistics. New earnings survey. 1998.
26. De Wals P, Blackburn M, Guay M, et al. Burden of chickenpox on families: a study in Quebec. Can J Infect Dis 2001;12:27-32.
27. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002;287:606-11.
28. Wallace MR, Chamberlin CJ, Zerboni L, et al. Reliability of a history of previous varicella infection in adults. JAMA 1997;278:1520-2.
29. Ronan K, Wallace MR. The utility of serologic testing for varicella in an adolescent population. Vaccine 2001;19:4700-2.